Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hepatitis B Clear all
Completed No phase listed Observational

Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.

NCT00263614
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2009 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

NCT02057263
View directory record Official record
Conditions
Hepatitis B
Interventions
Alendronate, Hepatitis B Vaccine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Jul 21, 2026, 6:45 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic

NCT07317687
View directory record Official record
Conditions
HIV Testing, HEPATITIS C (HCV), Syphilis, Hepatitis B Virus (HBV)
Interventions
Rapid Fingerstick Test, Blood Draw for lab test
Diagnostic Test
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Harpers Ferry, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pentavalent DTaP-Hep B-IPV

NCT00133445
View directory record Official record
Conditions
Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Interventions
DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 5 Days
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jul 21, 2026, 6:45 AM EDT
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Recruiting Phase 2 Interventional

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

NCT06092333
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
VIR-2218 and peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults

NCT01779505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GS-4774
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Jul 21, 2026, 6:45 AM EDT
Completed No phase listed Observational

Prevention of Recurrent Hepatitis B After Liver Transplantation

NCT00059267
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
Interventions
HBIG, Epivir, Hepsera
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Jul 21, 2026, 6:45 AM EDT
Terminated Phase 3 Interventional Results available

Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone

NCT00376259
View directory record Official record
Conditions
Hepatitis B
Interventions
telbivudine, adefovir dipivoxil
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
San Diego, California • San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

NCT00722332
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepaGam B
Biological
Lead sponsor
Cangene Corporation
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Increasing Hepatitis B Screening Among Korean Church Attendees

NCT00760721
View directory record Official record
Conditions
Hepatitis B
Interventions
Educational Small Group Session
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
1,123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Jul 21, 2026, 6:45 AM EDT
Completed No phase listed Observational

Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients

NCT01267162
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Medical Procare PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Los Angeles, California • San Jose, California • Flushing, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

NCT04142762
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

NCT01590641
View directory record Official record
Conditions
Hepatitis B, HBV
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

NCT02579382
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, Vesatolimod, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

NCT00410202
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Tenofovir, Adefovir, Lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Jul 21, 2026, 6:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers

NCT00005907
View directory record Official record
Conditions
Active Immunity, Healthy, Stem Cell Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:45 AM EDT
Terminated Not applicable Interventional

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

NCT01951209
View directory record Official record
Conditions
Liver Cirrhosis, Chronic Hepatitis C
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
David E. Kaplan, MD MSc
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects

NCT04309526
View directory record Official record
Conditions
Hepatitis B
Interventions
NCO-48 Fumarate, Placebo
Drug
Lead sponsor
Nucorion Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

NCT00197236
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix™, Infanrix™, ActHIB™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
22
States / cities
Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

NCT00106964
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
Engerix-B 20 mcg, Engerix-B 40 mcg, Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jul 21, 2026, 6:45 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Phase 3 Interventional

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

NCT05630820
View directory record Official record
Conditions
Chronic Hepatitis B, Hepatitis B, Chronic
Interventions
Bepirovirsen, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
12
States / cities
Centreville, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 6:45 AM EDT
Completed Not applicable Interventional Results available

FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy

NCT00125762
View directory record Official record
Conditions
Cirrhosis, Hepatitis B, Hepatitis C
Interventions
FibroScan
Device
Lead sponsor
Afdhal, Nezam, M.D.
Individual
Eligibility
18 Years to 90 Years
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jul 21, 2026, 6:45 AM EDT